Polymeric nanoparticles with therapeutic gene for gene therapy: I. Preparation and in vivo gene transfer study.
- Author:
Jing YANG
1
;
Cunxian SONG
;
Hongfan SUN
;
Li WU
;
Lina TANG
;
Xigang LENG
;
Pengyan WANG
;
Yiyao XU
;
Yongjun LI
;
Heng GUAN
Author Information
1. Institute of Biomedical Engineering, CAMS & PUMC, Tianjin 300192, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Disease Models, Animal;
Gene Transfer Techniques;
Genetic Therapy;
Genetic Vectors;
chemistry;
Lactic Acid;
chemistry;
Nanoparticles;
chemistry;
Plasmids;
Polyglycolic Acid;
chemistry;
Rabbits;
Vascular Endothelial Growth Factor A;
genetics
- From:
Journal of Biomedical Engineering
2005;22(3):438-442
- CountryChina
- Language:Chinese
-
Abstract:
VEGF nanoparticle (VEGF-NP) was prepared by a multi-emulsification technique using a biodegradable poly-dl-lactic-co-glycolic (PLGA) as matrix material. The nanoparticles were characterized for size, VEGF loading capacity, and in vitro release. VEGF-NP and naked VEGF plasmid were intramuscularly injected into the ischemia site of the rabbit chronic hindlimb ischemia model and the efficiency of VEGF-NP as gene delivery carrier for gene therapy in animal model was evaluated. Gene therapuetic effect was assessed evaluated by RT-PCR, immunohistochemistry and angiography assay. The average size of VEGF-NP was around 300 nm. The encapsulation efficiency of VEGF was above 96%. Loading amount of VEGF in the nanoparticles was about 4%. In vitro, nanoparticles maintained sustained-release of VEGF for two weeks. Two weeks post gene injection the capillary density in VEGF-NP group (81.22 per mm2) was significantly higher than that in control group (29.54 mm2). RT-PCR results showed greatly higher VEGF expression in VEGF-NP group (31.79au * mm) than that in naked VEGF group (9.15 au * mm). As a carrier system for gene therapy in animal model, VEGF-NP is much better than naked DNA plasmid. The results demonstrate great possibility of using NP carrier in human gene therapy.
